New therapeutic developments in renal cell cancer

被引：4

作者：

Prenen, Hans ^{[1
,2
]}

Gil, Thierry ^{[2
]}

Awada, Ahmad ^{[2
]}

机构：

[1] Catholic Univ Louvain, Univ Hosp Gasthuisberg, Dept Gen Med Oncol, B-3000 Louvain, Belgium

[2] Inst Jules Bordet, Dept Med, Med Oncol Clin, B-1000 Brussels, Belgium

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2009年 / 69卷 / 01期

关键词：

Renal cell cancer; Molecular targeted therapy; Angiogenesis; Sunitinib; Sorafenib; Temsirolimus; ENDOTHELIAL GROWTH-FACTOR; RANDOMIZED DISCONTINUATION TRIAL; RADICAL NEPHRECTOMY; INTERFERON-ALPHA; PHASE-II; ANTITUMOR-ACTIVITY; TUMOR PROGRESSION; KINASE INHIBITOR; CARCINOMA; INTERLEUKIN-2;

D O I：

10.1016/j.critrevonc.2008.07.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Metastatic renal cell cancer is associated with a poor prognosis and is very resistant to conventional cytotoxic chemotherapy. Progress in the understanding of molecular biology and pathogenesis of renal cell cancer has been translated into the development of new therapeutic strategies. The recent approval Of sunitinib, sorafenib, temsirolimus and bevacizumab in combination with IFN-alpha has revolutionized the management of renal cell carcinoma. In this review, we describe the status of current treatment strategies for metastatic renal cell cancer and We focus Oil the new compounds including targeted therapy such as new anti-angiogenic and mTOR inhibitors. (c) 2008 Elsevier Ireland Ltd. All rights reserved.

引用

页码：56 / 63

页数：8

共 57 条

[1]

Amato RJ, 2007, J CLIN ONCOL, V25

[2] Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].

Atkins, MB ;

Hidalgo, M ;

Stadler, WM ;

Logan, TF ;

Dutcher, JP ;

Hudes, GR ;

Park, Y ;

Lion, SH ;

Marshall, B ;

Boni, JP ;

Dukart, G ;

Sherman, ML .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918

[3] Anti-angiogenic therapy in the treatment of advanced renal cell cancer [J].

Board, Ruth E. ;

Thistlethwaite, Fiona C. ;

Hawkins, Robert E. .

CANCER TREATMENT REVIEWS, 2007, 33 (01) :1-8

[4] Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: A cytokine working group randomized trial [J].

Clark, JI ;

Atkins, MB ;

Urba, WJ ;

Creech, S ;

Figlin, RA ;

Dutcher, JP ;

Flaherty, L ;

Sosman, JA ;

Logan, TF ;

White, R ;

Weiss, GR ;

Redman, BG ;

Tretter, CPG ;

McDermott, D ;

Smith, JW ;

Gordon, MS ;

Margolin, KA .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (16) :3133-3140

[5]

DILMAN RO, 1993, CANCER, V71, P2358

[6]

DUTCHER JP, 2007, P AN M AM SOC CLIN, V25, pS243

[7] Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial [J].

Escudier, Bernard ;

Pluzanska, Anna ;

Koralewski, Piotr ;

Ravaud, Alain ;

Bracarda, Sergio ;

Szczylik, Cezary ;

Chevreau, Christine ;

Filipek, Marek ;

Melichar, Bohuslav ;

Bajetta, Emilio ;

Gorbunova, Vera ;

Bay, Jacques-Olivier ;

Bodrogi, Istvan ;

Jagiello-Gruszfeld, Agnieszka ;

Moore, Nicola .

LANCET, 2007, 370 (9605) :2103-2111

[8] Sorafenib in advanced clear-cell renal-cell carcinoma [J].

Escudier, Bernard ;

Eisen, Tim ;

Stadler, Walter M. ;

Szczylik, Cezary ;

Oudard, Stephane ;

Siebels, Michael ;

Negrier, Sylvie ;

Chevreau, Christine ;

Solska, Ewa ;

Desai, Apurva A. ;

Rolland, Frederic ;

Demkow, Tomasz ;

Hutson, Thomas E. ;

Gore, Martin ;

Freeman, Scott ;

Schwartz, Brian ;

Shan, Minghua ;

Simantov, Ronit ;

Bukowski, Ronald M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134

[9] Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer [J].

Flanigan, RC ;

Salmon, SE ;

Blumenstein, BA ;

Bearman, SI ;

Roy, V ;

McGrath, PC ;

Caton, JR ;

Munshi, N ;

Crawford, ED .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (23) :1655-1659

[10] RECOMBINANT INTERFERON ALFA-2A WITH OR WITHOUT VINBLASTINE IN METASTATIC RENAL-CELL CARCINOMA - RESULTS OF A EUROPEAN MULTICENTER PHASE-III STUDY [J].

FOSSA, SD ;

MARTINELLI, G ;

OTTO, U ;

SCHNEIDER, G ;

WANDER, H ;

OBERLING, F ;

BAUER, HW ;

ACHTNICHT, U ;

HOLDENER, EE .

ANNALS OF ONCOLOGY, 1992, 3 (04) :301-305

← 1 2 3 4 5 6 →